ARTICLE COVER SHEET

LWW

Journal of The North American Menopause Society FLA, EDI

Article : gme20337 Creator : dx60 Date : Thursday April 19th 2007 Time : 17:38:28 Article Title : Expression of calcitonin gene-related peptide, adrenomedullin, and receptor modifying proteins in human adipose tissue and alteration in their expression with menopause status Number of Pages (including this page) : 10 Template Version : 1.4 09/27/06 Scripts: 1. sc_Extract_Xml 2. AssymFrame

Copyright © 2007 The North American Menopause Society. Unauthorized reproduction of this article is prohibited.

Expression of calcitonin gene-related peptide, adrenomedullin, and receptor modifying proteins in human adipose tissue and alteration in their expression with menopause status

Pratima Gupta, MD, MRCOG,^{1,2} Alison L. Harte, BMedSci, PhD,² Nancy F. da Silva,² Hassan Khan,² Anthony H. Barnett, MD, BSc(Hons), FRCP,³ Sudhesh Kumar, MD, FRCP,² David W. Sturdee, MD, FRCOG,¹ and Philip G. McTernan, PhD, BSc²

Abstract

Objective: Calcitonin gene-related peptide (CGRP) is a vasoactive, proinflammatory neuropeptide implicated in the pathogenesis of cardiovascular disease. Elevated CGRP levels during hot flushes and pregnancy suggest that reproductive hormones may influence CGRP secretion. CGRP and the related protein adrenomedullin (ADM) may function through adipose tissue–mediated effects, since adipose tissue is an important site of cytokine production and the main site for estrogen production after menopause. This study examined mRNA and protein expression of CGRP, ADM, and the receptor activity-modifying proteins and the effects of menopausal status in human adipose tissue.

Design: Protein/mRNA levels were determined in adipose tissue biopsy samples collected from premenopausal (n = 22: follicle-stimulating hormone, <20 IU/L; estradiol [mean \pm SE], 434.5 \pm 87.81 pmol/L) and postmenopausal (n = 25: follicle-stimulating hormone, >20 IU/L; estradiol, 43.4 \pm 6.95 pmol/L) women.

Results: Our studies determined that CGRP, ADM, and receptor activity-modifying proteins were expressed in abdominal fat, adipocytes, and preadipocytes. CGRP and ADM mRNA levels were increased in abdominal subcutaneous fat in postmenopausal women compared with premenopausal women (β CGRP: premenopause Δ cycle threshold [Ct], 31.07 ± 0.28 vs postmenopause Δ Ct, 30.35 ± 0.17 , P = 0.035; ADM: premenopause Sc Δ Ct, 12.41 ± 0.2 vs postmenopause Sc Δ Ct, 11.55 ± 0.14 , P < 0.001) with CGRP differentially expressed in subcutaneous and omental depots. CGRP protein expression was higher in postmenopausal women (P < 0.05) in both fat depots.

Conclusions: Our findings suggest that adipose tissue represents an important site for CGRP and ADM production and that menopause status alters their expression in abdominal fat. This offers a potential mechanism to explain the role of CGRP in menopausal vasomotor symptoms and the increased risk of cardiovascular disease in postmenopausal women.

Key Words: Calcitonin gene-related peptide – Adrenomedullin receptor-modifying proteins – Menopause – Adipose tissue.

he menopausal transition in women is associated with weight gain, increased visceral fat content, and central adiposity.¹ Although recent studies have shown higher body mass index (BMI) to be associated with increased

Financial disclosure: None reported.

severity of hot flushes in postmenopausal women,²⁻⁷ the mechanisms through which adipose tissue (AT) influences the severity of these symptoms is not yet known. Calcitonin generelated peptide (CGRP), a vasoactive peptide, may have a role in the onset of hot flushes. Elevated CGRP serum levels have been observed during hot flushes in postmenopausal women and in men after castration,⁸⁻¹⁰ linking acute release of CGRP with the onset of vasomotor symptoms. Animal and human studies have demonstrated that secretion and activity of CGRP and adrenomedullin (ADM) are influenced by the sex hormones. Increased plasma levels of CGRP have been noted during pregnancy, although its hypotensive effects were potentiated in the presence of the sex hormones.^{11,12} In postmenopausal women, hormone therapy (HT) was associated with increased plasma CGRP levels.¹³ Similarly, circulatory ADM levels are influenced by the phase of menstrual

Received October 19, 2006; revised and accepted January 9, 2007.

From the ¹Women's Unit, Solihull Hospital and University of Birmingham, Heart of England NHS Foundation Trust, Lode Lane Solihull, West Midlands, UK; ²Unit for Diabetes and Metabolism, Warwick Medical School Research Wing, Clinical Sciences Building, UHCW Trust, Clifford Bridge Road, Walsgrave, Coventry, UK; and ³Department of Medicine, University of Birmingham and Heart of England NHS Foundation Trust, Birmingham, UK.

Address correspondence to: Pratima Gupta, MD, MRCOG, Department of Obstetrics and Gynaecology, Warwick Hospital, Lakin Road, Warwick, CV34 5BW. E-mail: guptap@tiscali.co.uk

cycle, and plasma levels are increased during normal pregnancy.^{14,15}

CGRP is a 37-amino-acid neuropeptide that exists in two forms, α and beta β , that differ by three amino acids in humans.¹⁶ It is widely distributed throughout the body, with α CGRP being the predominant form in the central and peripheral nervous system, although β CGRP is present in the enteric system and pituitary gland.¹⁷ However, the importance of their differential distribution and regulation in vivo is not yet clear. Both isoforms have potent vasodilatory capacity, although studies have suggested they may have different signaling and regulatory mechanisms at the receptor level.^{18,19}

ADM, a 52-amino-acid peptide, is another member of the calcitonin family and is produced by a variety of cells, including vascular endothelial and smooth muscle cells.²⁰ Although ADM is mainly active at the microvasculature level, it is also present in the circulation in considerable amounts.^{21,22} CGRP is secreted in the tissues by sensory nerves and rapidly metabolized by tissue endopeptidases; therefore, the small amount detectable in the circulation is thought to be a spillover from the perivascular sensory nerve endings.^{23,24} These studies suggest that local paracrine effects may be more important than its systemic influence. Both CGRP and ADM bind to a common receptor molecule called calcitonin receptor-like receptor (CRLR); however, for the receptor to be functional, an additional transmembrane protein called receptor activity-modifying protein (RAMP) is required. Three RAMPs (RAMP1, RAMP2, RAMP3) determine the specificity of the receptor to either CGRP or ADM because in the presence of RAMP1, the CRLR acts primarily as a CGRP receptor, whereas in the presence of RAMP2 and RAMP3, it acts as an ADM receptor (ADM₁ and ADM₂). Alteration in RAMP expression provides another potential mechanism through which cells may change their responsiveness to CGRP and ADM.²⁵

We hypothesized that the local activity of AT-derived CGRP may influence the severity of hot flushes by regulating cutaneous vasodilatation. Therefore, the aim of the study was to determine whether CGRP was expressed in human AT and whether its expression was altered by menopausal status. Because many AT-derived cytokines are depot specific, we examined the expression of CGRP in paired samples of subcutaneous (Sc) and omental (Om) AT. In addition, we explored the possibility that expression of ADM and the RAMPs in human AT may be influenced by menopause status.

Participants

METHODS

For these studies, fasting blood samples (n = 31: premenopausal, 22; postmenopausal, 9) and paired Sc and Om AT samples were obtained from premenopausal and postmenopausal women (n = 30: premenopausal, 22; postmenopausal, 8) undergoing elective abdominal surgery for benign conditions. Additionally, 17 unpaired abdominal Sc

(AbSc) AT samples were also collected from postmenopausal women. Postmenopausal status was defined as amenorrhea for more than 12 months along with serum follicle-stimulating hormone (FSH) levels greater than 20 IU/L. In total, 77 ex vivo AT samples were analyzed, comprising premenopausal AbSc (n = 22), premenopausal abdominal Om (AbOm) (n = 22), postmenopausal AbSc (n = 25), and postmenopausal AbOm (n = 8). Women with any medical condition (ie, hypertension, cardiovascular disease, thyroid disorders, renal disorders, diabetes, or chronic pain conditions) were excluded from the study. None of the women were on endocrine therapy (ie, HT, tamoxifen, steroids, or antiglycemic agents) or any medication that might have influenced CGRP secretion. All samples were collected in accordance with the research protocol approved by the Solihull Local Research Ethics Committee.

Collection of clinical data

Anthropometric data were collected to calculate BMI and waist-hip ratio. Systolic and diastolic blood pressures were recorded before sample collection. The date of last menstrual period, cycle length, and regularity were recorded to determine the menopause status in postmenopausal women (last menstrual period 1-36 y) and phase of menstrual cycle in premenopausal women. Women who were within the last 2 weeks of their cycle were classified as being in the luteal phase (n = 11), and women who were in the earlier part of their cycle were classified as being in the follicular phase (n = 6).

Collection, storage and analysis of samples

Fasting blood samples (minimum 6 h) were collected and analyzed for serum glucose, insulin, estradiol, and FSH. After collection, the serum and AT samples were immediately stored at -80° C until they were required for analysis. Estradiol, FSH, and luteinizing hormone levels were determined using electrochemiluminescence immunoassays (Roche Diagnostics) (estradiol reference range, 18.4-15,781 pmol/L; coefficient of variation [CV]: intrabatch, 5.7%; interbatch, 6.2%; FSH reference range, 0.1-200 IU/L; CV intrabatch, 2.8%; interbatch, 4.5%; luteinizing hormone reference range, 0.1-200 mIU/mL; CV intrabatch, 1.8%; interbatch, 5.2%). The samples for serum glucose were collected into fluoride oxalate tubes and analyzed using an automated colorimetric method (Roche Diagnostics) (reference range, 3.89-6.38 mmol/L; CV intrabatch, 0.9%; interbatch, 1.8%). Serum insulin levels were determined using a solid-phase enzyme amplified sensitivity immunoassay (Linco Research Inc) (reference range, 2-200 µU/mL; CV intra-assay, 5.96%; interassay, 10.3%). HOMA scores were calculated as fasting glucose (mmol/L) \times fasting insulin (μ IU/mL)/22.5.

Isolation and culture of mature adipocytes and preadipocytes

In brief, 10 to 20 g (wet weight) of fresh AT was collected. Tissue was initially washed with $1 \times$ Hanks' balanced salt solution containing penicillin (100 U/mL) and streptomycin (100 μ g/mL). Visible blood vessels and connective tissue

2 Menopause, Vol. 14, No. 6, 2007

AQ2

were removed, and the tissue was finely chopped. All AT was digested with the same batch of collagenase class 1 (2 mg/mL, Worthington Biochemical Corp) in 1× Hanks' balanced salt solution (Gibco, Paisley, UK) for 20 minutes at 37°C.²⁶ The disrupted tissue was filtered through a double-layered cotton mesh, and preadipocytes and adipocytes were separated by centrifugation at 360g for 5 minutes. The upper layer of mature adipocytes was then removed from the collagenase-dispersed preparation, washed in phenol red-free medium Dulbecco modified Eagle medium (DMEM:F12) twice, and centrifuged at 360g for 2 minutes. The isolated adipocytes (1 mL, consisting of approximately 500,000 mature adipocytes) were maintained in flasks (25 cm²) of DMEM:F12 containing 15 mmol/L glucose, penicillin (100 U/mL) and streptomycin (100 μ g/mL) for 48 hours.

Protein extraction and quantification from adipose tissue and adipocytes

Proteins were extracted from whole AT using the Cambridge radioimmunoprecipitation assay protein extraction method.²⁷ AT (100 mg) was resuspended in 300 μ L radioimmunoprecipitation assay buffer and homogenized for 30 seconds (Fisher Scientific). The resulting mixture was then flash frozen, allowed to thaw at room temperature, and subsequently spun at 13,000 rpm for 30 minutes at 4°C. Infranatant was collected and stored at -80° C. The methodology for protein extraction from adipocytes and preadipocytes was identical to AT except that 500 μ L of the cell sample was mixed with 200 μ L of radioimmunoprecipitation assay buffer before flash freezing and spinning. After extraction, protein concentrations were determined using the Bio-Rad detergent-compatible protein assay kit.²⁸

RNA extraction from adipose tissue, adipocytes, and preadipocytes

Total RNA was isolated from whole AT, adipocytes, and preadipocytes using a column-based method, according to the manufacturer's instructions (RNeasy Lipid Tissue Mini Kit, Qiagen). After RNA extraction, a DNA digestion step was performed (DNase Kit, Sigma) to remove any contaminating genomic DNA. RNA from adipocytes and preadipocytes was also extracted in a similar manner. RNA (1 μ g) from each sample was reverse-transcribed using RevertAid H minus M-MuLV reverse-transcriptase (Fermentas) and random hexamers, in accordance with the manufacturer's instructions.

Real-time polymerase chain reaction

The reverse transcriptase–polymerase chain reaction (RT-PCR) was performed on the 7700 sequence detection system in 25 μ L volumes on 96-well plates in a reaction buffer containing Taqman universal PCR master mix (containing 1.25 U AmpliTaq Gold DNA polymerase, 1.25 U AmpErase UNG, 200 μ mol deoxyribonucleoside triphosphate with deoxyuridine triphosphate passive reference and optimized buffer component), 100 to 200 nmol Taqman probe, 900 nmol primers, and 15 to 30 ng cDNA. Previously detailed primer and probe sequences for the *CD45* gene were used to

analyze CD45 mRNA expression.²⁷ Previous studies have highlighted CGRP mRNA expression in macrophages.^{29,30} Therefore, we assessed AT depots and isolated adipocytes, examining the impact of CGRP expression attributable to macrophages by using CD45 as a marker for macrophages. Quantitative primer and probe sequences for CD45 were forward primer 5' CGT AAT GGA AGT GCT GCA ATG T 3'. reverse primer 5' CTG GGA GGC CTA CAC TTG ACA 3', and Taqman probe 5' ACA ACT AAA AGT GCT CCT CCA AGC CAG GTC T 3' (accession number NM 080922).²⁷ The mRNA levels for αCGRP, βCGRP, ADM, RAMP1, RAMP2, and RAMP3 were analyzed using ABI predesigned gene expression assay-on-demand kits (Applera, Warrington, UK). All reactions were multiplexed with the housekeeping gene 18S, provided as a preoptimized control probe (Applera), enabling data to be expressed in relation to an internal reference to allow for differences in reverse-transcription efficiency.

Reactions were as follows: 50°C for 2 minutes and 95°C for 10 minutes, and then 44 cycles at 95°C for 15 seconds and 16°C for 1 minute. The data were obtained as cycle threshold (Ct) values according to the manufacturer's guidelines (the cycle number at which the logarithmic PCR plot crosses a calculated threshold line) and used to determine Δ Ct values (Δ Ct = Ct of the gene of interest



FIG. 1. The mean relative fold difference in mRNA expression of α CGRP (A) and β CGRP (B) in premenopausal omental (Pre Om), postmenopausal subcutaneous (Post Sc), and postmenopausal omental (Post Om) adipose tissue depots relative to the premenopausal subcutaneous (Pre Sc) adipose depot. The *18S* gene has been used as a preoptimized control probe (Applera, Warrington, UK). CGRP, calcitonin gene-related peptide; Ct, cycle threshold.



FIG. 2. The standardized mean expression of CGRP protein (\pm SEM) in human subcutaneous (Sc) and omental (Om) adipose tissue depots of premenopausal (Pre) and postmenopausal (Post) adipose tissue depots, by Western blot. Autoradiographs quantified by densitometry using a Gelbase/Gelblot program (UVP Ltd). Statistical analysis compared expression of CGRP in premenopausal depots versus postmenopausal depots. Representative Western blots for CGRP and the precursor protein are shown at top. The α tubulin Western blot (uppermost) demonstrates equal loading of the protein. CGRP, calcitonin generelated peptide.

minus Ct of the 18S gene). A lower Δ Ct value means the earlier appearance of the gene and thus higher expression of the gene. All measurements were carried out in triplicate for each sample. The individual Δ Ct values were averaged for all samples for comparisons among participants and the depots of the same participants. Similarly, the Δ Ct values for each group of AT biopsy samples (premenopausal Sc, premenopausal Om, postmenopausal Sc, postmenopausal Om) were averaged to calculate a group mean, SD, and SEM for each depot. Independent *t* tests were used to analyze the group means for each depot. The relative fold

F1-F4 difference (as shown in Figs. 1-4) for all the mRNA expression was calculated using the premenopausal AbSc group as a reference, which was given an arbitrary value of 1. All the data were statistically analyzed at the Δ Ct stage to avoid potential bias of averaging data that had been transformed through the equation $2^{-\Delta\Delta Ct}$.

ADM ACt (mean \pm SEM) 12.41 \pm 0.2 12.53 ± 0.36 12.11 ± 0.24 11.55 ± 0.14 P < 0.001 Vs Relative expression of ADM mRNA to PreSc depots Pre So 1.5 P < 0.03 VsPost Sc 1 0.5 Λ Pre Sc Pre Om Post Sc Post Om (n = 22)(n = 22) (n = 25)(n = 8)Adipose tissue depots

FIG. 3. The relative fold difference in mRNA expression of adrenomedullin (ADM) in premenopausal omental (Pre Om), postmenopausal subcutaneous (Post Sc), and postmenopausal omental (Post Om) adipose tissue depots relative to the premenopausal subcutaneous (Pre Sc) adipose depot. The *18S* gene has been used as a preoptimized control probe (Applera, Warrington, UK). Ct, cycle threshold.

4 Menopause, Vol. 14, No. 6, 2007

Western blot

For Western blot analysis, 20 μ g of AT protein samples were loaded onto a 15% polyacrylamide gel. After gel electrophoresis and electroblotting, the membrane was incubated with a primary monoclonal mouse antibody for human CGRP (Biohit Diagnostics, Devon, UK). Detection of CGRP was achieved using a horseradish peroxidase-conjugated secondary antibody (Binding Site, Birmingham, UK) diluted 1:80,000 in phosphate-buffered saline-T (0.05%T). A chemiluminescent detection system (ECL Advanced, Amersham Pharmacia Biotech, Little Chalfont, UK) was used to visualize bands after x-ray exposure. In addition, 40 μ g of mature adipocytes and 40 μ g of preadipocytes were used to assess CGRP protein expression. Autoradiographs were quantified by densitometry using a Gelbase/Gelblot program (UVP Ltd).



FIG. 4. The relative fold difference in mRNA expression of RAMP1 (A), 2 (B), and 3 (C) in premenopausal omental (Pre Om), postmenopausal subcutaneous (Post Sc), and postmenopausal omental (Post Om) adipose tissue depots relative to the premenopausal subcutaneous (Pre Sc) adipose depot. The *18S* gene has been used as a preoptimized control probe (Applera, Warrington, UK). RAMP, receptor activity-modifying protein; Ct, cycle threshold.

© 2007 The North American Menopause Society

Statistical analysis

Statistical analysis was performed using SPSS statistical software (version 12). Paired and unpaired Student t tests were used to analyze the expression of mRNA and proteins. Correlations for continuous variables affecting CGRP, ADM, and RAMP mRNA expression were determined by calculating Pearson correlation coefficients. The significance threshold was taken as P < 0.05. The data are presented as mean \pm SEM unless stated otherwise.

RESULTS

Baseline characteristics

As expected, the postmenopausal women were older (mean age: pre, 43.3 ± 1.51 y; post, 59.8 ± 1.77 y), had lower mean serum estradiol levels (pre, 434.5 ± 87.81 pmol/L; post, 43.3 ± 6.95 pmol/L), and higher mean serum FSH levels (pre, 9.1 ± 2.67 IU/L; post, 63.6 ± 9.72 IU/L). Mean systolic blood pressure was higher in the postmenopausal group (P =(0.015); however, the two groups were comparable in mean diastolic blood pressure, BMI, waist circumference, waist-**T1** hip ratio, serum glucose, and insulin levels (Table 1).

CGRP mRNA expression in adipose tissue, mature adipocytes, and preadipocytes

Both α CGRP and β CGRP mRNA were expressed in AbSc and Om AT depots. The α CGRP expression was similar in Sc and Om AT, but the expression was significantly lower in the Om depot from postmenopausal women compared with that from the premenopausal women (mean \pm SEM Δ Ct: premenopausal Sc, 29.45 \pm 0.6; premenopausal Om, 29.06 \pm 0.44; postmenopausal Sc, 30.1 \pm 0.26; postmenopausal Om, 30.11 ± 0.26) (Fig. 1A). The BCGRP showed higher expression in both Sc and Om adipose depots from the postmenopausal women than from the premenopausal women (mean \pm SEM Δ Ct: premenopausal Sc, 31.07 ± 0.28 ; premenopausal Om, 30.63 ± 0.24 ; postmenopausal Sc, 30.35 ± 0.17 ; postmenopausal Om, 30.15 ± 0.36) (Fig. 1B). CGRP mRNA was also found to be expressed by mature adipocytes (n = 6) and preadipocytes (n = 9). However, this was not attributed to macrophage contamination, as CD45, the macrophage marker, remained undetected in preadipocytes and mature adipocytes.

TABLE 1.	Population characteristics of premenopausal	and
	postmenopausal groups	

	Premenopausal $(n = 22)$	Postmenopausal $(n = 25)$	Р
Age, y	43.32 (1.51)	59.80 (1.76)	< 0.001
BMI, kg/m ²	27.43 (1.03)	27.25 (0.79)	0.89
Waist circumference, cm	87.43 (2.47)	87.47 (3.03)	0.99
Waist-hip ratio	0.83 (0.01)	0.81 (0.02)	0.30
Mean systolic BP, mm Hg	125.33 (3.52)	145.56 (8.69)	0.05
Mean diastolic BP, mm Hg	75.05 (1.95)	83.00 (5.16)	0.086
Serum glucose, mmol/L	5.14 (0.20)	5.12 (0.21)	0.97
Serum insulin, µU/mL	7.05 (1.34)	11.35 (3.65)	0.18

Values are mean (SEM). BP, blood pressure.

CGRP protein expression in adipose tissue, mature adipocytes, and preadipocytes

Western blotting showed that CGRP was expressed in all AT depots (Fig. 2) as well as mature adipocytes and preadipocytes (data not shown). Sc and Om AT depots from the postmenopausal women showed higher expression of CGRP protein compared with the premenopausal women (P < 0.05), although no difference in CGRP protein expression was observed between Sc and Om depots (Fig. 2).

Expression of ADM mRNA in adipose tissue and mature adipocytes

ADM was highly expressed in all the AT depots (mean \pm SEM Δ Ct: premenopausal Sc, 12.41 ± 0.2; premenopausal Om, 12.11 ± 0.24 ; postmenopausal Sc, 11.55 ± 0.14 ; postmenopausal Om, 12.53 \pm 0.36). The postmenopausal Sc adipose depot showed a 1.8-fold increase in ADM expression compared with the premenopausal Sc tissue (P < 0.001; Fig. 3). The ADM was also expressed in isolated adipocytes (data not shown).

Expression of RAMPs (1, 2, 3) mRNA in adipose tissue and mature adipocytes

All three RAMPs were expressed in Sc and Om AT, with RAMP2 showing the highest expression overall. RAMP expression was not influenced by menopause status as no differential expression was observed (Fig. 4A-C). Only RAMP1 showed depot-specific gene expression, with the Om depots showing increased mRNA expression (pre Sc/pre Om, 1:6.6; pre Sc/post Om, 1:18). The RAMPs were also expressed in isolated adipocytes, with RAMP2 again showing greatest mRNA expression (mean \pm SEM Δ Ct: RAMP1, 22.66 ± 0.94; RAMP2, 17.07 ± 0.87; RAMP3, 29.08 ± 1.55).

Effects of menstrual phase on CGRP, ADM, and RAMP mRNA expression

Among premenopausal women, the expression of α CGRP mRNA was higher in women in follicular phase of the menstrual cycle compared with those in the luteal phase (mean \pm SEM Δ Ct: follicular, 28.11 \pm 0.54; luteal, 30.42 \pm 0.60, P = 0.01). No effect of menstrual phase was observed on mRNA expression of BCGRP, ADM, or any of the RAMPs.

Effects of covariates on CGRP, ADM, and RAMP mRNA expression

ADM mRNA expression and BCGRP mRNA were positively correlated with age (β CGRP: r = -0.25, P =0.028; ADM: r = -0.279, P = 0.014), suggesting a higher expression of these mRNA in older women. aCGRP mRNA expression, however, did not show such a correlation, suggesting no influence of age on the expression of $\alpha CGRP$ mRNA. ADM and aCGRP were positively correlated with each other (r = 0.394, P = 0.001); however, there was no correlation of ADM and α CGRP with any of the RAMPs. βCGRP mRNA expression was positively correlated with RAMP2 (r = 0.586, P < 0.001) and RAMP1 when controlled for age (r = 0.555, P = 0.001), the two RAMPs necessary for binding of β CGRP to the receptor indicating a simultaneous



FIG. 5. Bivariate correlations between mRNA expression (expressed as Δ Ct values) of β CGRP with age (**A**), adrenomedullin (ADM) with age (**B**), ADM with α CGRP (**C**), RAMP3 with waist-hip ratio (**D**), β CGRP with RAMP2 (**E**), and β CGRP with RAMP3 (**F**). CGRP, calcitonin gene-related peptide; Ct, cycle threshold; RAMP, receptor activity-modifying protein.

up-regulation of their mRNA expression. RAMP2 expression was positively correlated with RAMP3 mRNA levels (r = 0.346, P = 0.002). Furthermore, RAMP3 showed lower mRNA expression in women with increasing waist-hip ratio, [F5] ie, central adiposity (r = 0.33, P = 0.009) (Fig. 5A-F).

DISCUSSION

CGRP is widely recognized as a neuropeptide released from sensory nerves in the central and peripheral nervous systems. The present study demonstrates that CGRP is actively expressed at the mRNA and protein level in human AT as well as in isolated mature adipocytes. In addition, these studies have explored the potential mechanism of CGRP action through ADM and RAMPs by examining whether alteration in menopausal status affects receptor expression, which may influence the role of CGRP as a vasodilator. Our findings have established that AT and, more specifically, isolated adipocytes act as a source of CGRP and ADM. Furthermore, AbSc AT taken from postmenopausal women has increased CGRP and ADM protein expression as compared with that from premenopausal women.

Because of the homogeneity of α CGRP and β CGRP, it was not possible to discriminate between the two isoforms at the protein level. However, our mRNA findings suggest that the higher level of CGRP protein in the AT from postmenopausal women may arise from increased expression of β CGRP, as the expression of α CGRP mRNA was much lower in postmenopausal women compared with β CGRP. This is consistent with previous findings, which have highlighted β CGRP as the prevalent form in the enteric system.¹⁷ Studies have also suggested that α CGRP and β CGRP bind differently to the receptors and may have different responses to their antagonists. Whereas α CGRP mainly binds to the CGRP₁ receptor, formed by the association of CRLR with RAMP1, β CGRP may also bind to the ADM receptor (ADM₂) formed by the association of CRLR and RAMP3.³¹ The linear correlation between β CGRP mRNA and RAMPs 1, 2, and 3 observed in our study indicates that, in AT, β CGRP may potentially be acting through the ADM receptors in addition to CGRP. The importance of this finding in vivo is not yet known.

CGRP is one of the many neuropeptides that have been studied to understand the complex pathogenesis of menopausal hot flushes. It is known that both neurogenic and humoral mechanisms are involved in the altered cutaneous thermoregulation, which is controlled by both the sympathetic and sensory nervous systems via release of peptides such as norepinephrine, neuropeptide Y, CGRP, and neurokinin A.^{32,33} AT is a peripheral vascularized site that, by regulating the production of CGRP, may participate in regulating the cutaneous blood flow. Studies in rats have shown that neuropeptides derived from the sympathetic nerves located in white AT may influence lipid mobilization.³⁴

Furthermore, CGRP was found to support recruitment and differentiation of periovarian brown adipocytes in cold acclimated rats, suggesting its active involvement in AT metabolism.35 The presence of CGRP in AT not only supports the role of CGRP in maintaining body temperature, because of its potent vasodilatory ability, but also provides a possible mechanism by which AT may influence the severity of hot flushes in postmenopausal women. Local administration of CGRP-enhanced methacholine chloride induced sweating in human volunteers, indicating that the occurrence of sweats, after hot flushes, may be mediated through CGRP.³⁶ Visceral fat deposition is considered more pathogenic than Sc AT and has been shown to increase the relative risk of coronary heart disease-related deaths in postmenopausal women.³⁷ Visceral AT is metabolically more active than Sc AT because it is able to mobilize free fatty acids more readily.³⁸ Therefore, paired samples of Sc and Om AT were used in this study to investigate the differential expression of CGRP and ADM in relation to fat depot and to explore the mechanisms by which CGRP may influence cardiovascular risk. We found a significantly higher expression of RAMP1 in the Om fat tissue compared with the Sc tissue, which indicates a possible mechanism by which postmenopausal central adiposity may influence CGRP activity. Previous studies by Wimalawansa³⁹ suggest that age may potentially influence CGRP expression in certain tissues, although conflicting studies have shown no such relationship.^{40,41} In the study by Schifter,⁴⁰ 232 healthy individuals (109 male, 123 female) between 18 to 79 years of age showed CGRP secretion to be unaffected by age. Similarly, age was not found to affect the tissue contents of CGRP in a study by Zaidi and colleagues.⁴¹

In a similar manner to CGRP, ADM also acts as a potent vasodilator and plays an important role in maintaining vascular homeostasis. AT has previously been reported to express ADM mRNA.^{42,43} Our findings demonstrated that ADM was highly expressed by human AT and adipocytes, which is also influenced by menopause status. Overproduction of ADM has been found to be associated with the existence of cardiovascular disease, and increased circulatory levels may have a prognostic value in some cardiovascular diseases.^{20,21} Our studies indicate that higher expression of ADM in AbSc AT, after menopause, may act as a contributing source to cardiovascular risk associated with menopause. Whether ADM is involved in vasodilatation during hot flushes is, as yet, unknown, but intravenous administration of ADM has been reported to cause skin flushing, a phenomenon similar to CGRP.44 Although ADM is mainly depicted as a circulatory peptide, local paracrine effects in AT may represent an important site to maintain normal microvasculature homeostasis. As such, increased ADM mRNA expression in AT from postmenopausal women indicates its possible involvement in the pathogenesis of hot flushes along with CGRP.

It should be noted that in the study design, it was important to ascertain BMI-matched pre- and postmeno-

pausal women to ensure that the effects we observed between the two cohorts were due to menopause status and not adiposity. As such, this has limited the ability to examine the role of adiposity since the cohorts collected span a narrow BMI range. Consequently no significant correlations between aCGRP or BCGRP mRNA expression with BMI were noted; subsequent studies should examine this in further detail. In addition, because of our exclusion criteria, this study was unable to examine patients who had previously detailed severe vasomotor symptoms, such as those patients on HT. These patients were excluded because HT would influence AT metabolism and therefore may have influenced CGRP expression. However, future studies should explore the effects of estrogen directly on CGRP expression in AT as well as the effects of increased BMI on CGRP expression.

CONCLUSION

In conclusion, our studies demonstrated that AT may represent an important site for the production and local action of CGRP and ADM as important vasodilators. In addition, the mRNA expression of β CGRP with RAMP2 and RAMP3 positively correlated in human AT, suggesting the possibility that β CGRP may act via the ADM receptors. Taken together, these findings highlight the potential of AT as a site of vasodilatory action, which our studies have shown to be exacerbated by menopause status, with both ADM and CGRP potentially contributing to menopausal hot flashes as well as being associated with increased microvascular disease associated with age.

Acknowledgments: The authors thank Mr. David Burkitt and the gynecologists at Solihull Hospital and the general surgeons at Priory Hospital, Birmingham, for their help in collecting the tissue samples.

REFERENCES

- Toth MJ, Tchernof A, Sires CK, Poehlman ET. Menopause-related changes in body fat distribution. Ann N Y Acad Sci 2000;904:502-506.
- Gallicchio L, Visvanathan K, Miller SR, et al. Body mass, estrogen levels, and hot flashes in midlife women. *Am J Obstet Gynecol* 2005;193:1353-1360.
- Whiteman MK, Staropoli CA, Benedict JC, Borgeest C, Flaws JA. Risk factors for hot flashes in midlife women. J Women Health (Larchmt) 2003;12:459-472.
- Gold EB, Sternfed B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. *Am J Epidemiol* 2000;152:463-473.
- Chiechi LM, Ferreri R, Granieri M, Bianco G, Berardesca C, Loizzi P. Climacteric syndrome and body-weight. *Clin Exp Obstet Gynecol* 1997;24:163-166.
- Wilbur J, Miller AM, Montgomery A, Chandler P. Sociodemographic characteristics, biological factors, and symptom reporting in midlife women. *Menopause* 1998;5:43-51.
- Freeman EW, Sammel MD, Grisso JA, Battisni M, Garcia-Espagna B, Hollander L. Hot flashes in the late reproductive years: risk factors for African American and Caucasian women. J Womens Health Gend Based Med 2001;10:67-76.
- 8. Chen JT, Hirai Y, Seimiya Y, Hasumi K, Shiraki M. Menopausal flushes and calcitonin-gene-related peptide. *Lancet* 1993;342:49.

Menopause, Vol. 14, No. 6, 2007 7

- Wyon Y, Spetz AE, Theodorsson GE, Hammar ML. Concentration of calcitonin gene-related peptide and neuropeptide Y in plasma increases during flushes in postmenopausal women. *Menopause* 2000;7:25-30.
- Spetz AE, Pettersson B, Varenhorst E, Theodorsson E, Thorell LH, Hammar ML. Momentary increase in plasma calcitonin gene related peptide is involved in hot flashes in men treated with castration for carcinoma of the prostate. *J Urol* 2001;166:1720-1723.
- Yallampalli C, Chauhan M, Thota CS, Kondapaka S, Wimalawansa SJ. Calcitonin gene-related peptide in pregnancy and its emerging receptor heterogeneity. *Trends Endocrinol Metab* 2002;13:263-269.
- Gangula PR, Wimalawansa SJ, Yallampalli C. Pregnancy and sex steroid hormones enhance circulating calcitonin gene-related peptide concentrations in rats. *Hum Reprod* 2000;15:949-953.
- Spinetti A, Margutti A, Bertolini S, et al. Hormonal replacement therapy affects calcitonin gene-related peptide and atrial natriuretic peptide secretion in postmenopausal women. *Eur J Endocrinol* 1997; 137:664-669.
- Di Iorio R, Marinoni E, Letizia C, Villaccio B, Alberini A, Cosmi EV. Adrenomedullin production is increased in normal human pregnancy. *Eur J Endocrinol* 1999;140:201-206.
- Marinoni E, Di Iorio R, Letizia C, et al. Changes in plasma adrenomedullin levels during the menstrual cycle. *Regul Pept* 2000;87:15-18.
- Amara SG, Arriza JL, Leff SE, Swanson LW, Evans RM, Rosenfeld MG. Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene related peptide. *Science* 1985;229:1094-1097.
- 17. Mulderry PK, Ghatei MA, Spokes RA, et al. Differential expression of α -CGRP and β -CGRP by primary sensory neurons and enteric autonomic neurons in the rat. *Neuroscience* 1988;25:195-205.
- Hay DL, Howitt SG, Conner AC, Schindler M, Smith DM, Poyner DR. CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin receptors: a comparison of effects of adrenomedullin 22-52, CGRP6-37 and BIBN4096BS. Br J Pharmacol 2003;140:477-486.
- Wu D, Eberlein W, Rudolf K, Engel W, Hallermayer G, Doods H. Characterization of calcitonin gene-related peptide receptors in the rat atrium and vas deference: evidence for a [Cys(Et)(2,7)] hCGRPpreferring receptor. *Eur J Pharmacol* 2000;400:313-319.
- Beltowski J, Jamroz A. Adrenomedullin—what do we know 10 years since discovery? *Pol J Pharmacol* 2004;56:5-27.
- Kohno M, Hanehira T, Kano H, et al. Plasma adrenomedullin concentrations in essential hypertension. *Hypertension* 1996;27: 102-107.
- Takahashi K. Adrenomedullin from a pheochromocytoma to the eye: implications of the adrenomedullin research for endocrinology in the 21st century. *Exp Med* 2001;193:79-114.
- Le Greves P, Nyberg F, Hokfelt T, Terenius L. Calcitonin gene-related peptide is metabolized by an endopeptidase hydrolyzing substance P. *Regul Pept* 1989;25:277-286.
- Uddman R, Edvinsson L, Ekblad E, Hakanson R, Sundler F. Calcitonin gene related peptide (CGRP): perivascular distribution and vasodilatory effects. *Regul Pept* 1986;15:1-23.
- Poyner DR, Sexton PM, Marshall I, et al. International union of pharmacology. XXXII. The mammalian calcitonin gene related peptides, adrenomedullin, amylin and calcitonin receptors. *Pharmacol Rev* 2002;54:233-246.

- Rodbell M. Metabolism of isolated adipocytes. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 1964;239:375-380.
- McTernan PG, McTernan CL, Chetty R, et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002;87:2407-2410.
- Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976;72:807-811.
- Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Muller B. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. *Crit Care Med* 2004;32:1715-1721.
- Linscheid P, Seboek D, Zulewski H, Keller U, Muller B. Autocrine/ paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. *Endocrinology* 2005;146:2699-2708.
- Hay DL, Howitt SG, Conner AC, Schindler M, Smith DM, Poyner DR. CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin 22-52, CGRP8-37 and BIBN4096BS. *Br J Pharmacol* 2003;140: 477-486.
- 32. Freedman RR. Hot flushes revisited. Menopause 2000;7:3-4.
- Charkoudin N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. *Mayo Clin Proc* 2003;78:603-612.
- Bartness TJ, Kay Song C, Shi H, Bowers RR, Foster MT. Brain-adipose tissue talk. Proc Nutr Soc 2005;64:53-64.
- Giordano A, Morroni M, Carle F, Gesuita R, Marchesi GF, Cinti S. Sensory nerves affect the recruitment and differentiation of rat periovarian brown adipocytes during cold acclimation. *J Cell Sci* 1998;111:2587-2594.
- Kumazawa K, Sobue G, Mitsuma T, Ogawa T. Local effects of calcitonin gene-related peptide on human sweat gland function. *Rinsho Shinkeigaku* 1991;31:564-566.
- Prineas RJ, Folsom AR, Kaye SA. Central adiposity and increased risk of coronary artery disease mortality in older women. *Ann Epidemiol* 1993;3:35-41.
- 38. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. *Diabetes* 2000;49:883-888.
- Wimalawansa SJ. Age-related increase of calcitonin gene-related peptide in rat thyroid and circulation. *Peptides* 1991;12:1143-1147.
- Schifter S. Circulatory concentrations of calcitonin gene-related peptide (CGRP) in normal men determined with a new, highly sensitive radioimmunoassay. *Peptides* 1991;12:365-369.
- Zaidi M, Abeyasekera G, MacIntyre I. Calcitonin gene-related peptide: endocrine distribution and characterization of circulating forms. J Endocrinol Invest 1989;12:699-704.
- Fukai N, Yoshimoto T, Sugiyama T, et al. Concomitant expression of adrenomedullin and its receptor components in rat adipose tissues. *Am J Physiol Endocrinol Metab* 2005;288:E56-E62.
- 43. Harmancey R, Senard JM, Pathak A, et al. The vasoactive peptide adrenomedullin is secreted by adipocytes and inhibits lipolysis through NO-mediated β-adrenergic agonist oxidation. FASEB J 2005;19:1045-1047.
- 44. Meeran K, O'Shea D, Upton PD, et al. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab 1997;82:95-100.

8 Menopause, Vol. 14, No. 6, 2007

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES

- AQ1 = Subcutaneous fat meant by Sc? Please spell out here and below.
- AQ2 = Please spell out HOMA.
- AQ3 = Please confirm if the equation is correct.
- AQ4 = What does T stand for here? Please spell out.

END OF AUTHOR QUERIES

Author Reprints

For Rapid Ordering go to: www.lww.com/periodicals/author-reprints

Order		Menopause	2	Lippincott Williams & Wilkin a Wolters Kluwer business
Author(s) Name				
Title of Article				
*Article #		*Publication Mo/Yr		
*Fields may be left blank	if order is	placed before article numbe	er and publication	Use this form to
Quantity of Reprints _	\$	Reprint Pricing	Shipping	- order reprints. Publication fees, including color
Covers (Optional)	\$	200 copies = \$441.00 300 copies = \$510.00	orders shipping within the U.S.	separation charges and page charges wil be billed separately
Shipping Cost	\$	400 copies = \$585.00 500 copies = \$654.00	\$20.00 per 100 for orders shipping outside the U.S.	if applicable. Payment must be
Reprint Color Cost	\$	Covers \$108.00 for first 100	Tax	received before reprints can be shipped. Payment is
Tax	\$	copies \$18.00 each add'l 100 copies	residents add the appropriate tax or submit a tax exempt	accepted in the form of a check or credit card: purchase order
Total	\$	Reprint Color	form.	are accepted for orders billed to a
Ven men here included en		(\$70.00/100 reprints)		U.S. address.
You may have included col be invoiced separately. www.lww.com/periodical Payment MC VISA	or figures in If your artic s/author-rep	(\$70.00/100 reprints) n your article. The costs to cle contains color figures, prints.	publish those will use Rapid Ordering merican Express	<pre>U.S. address. Prices are subject t change without notice. Quantities over 500 copies: contact our Pharma Solutions Department at 410.528.4077</pre>
You may have included col be invoiced separately. www.lww.com/periodical Payment MC VISA Account #	or figures in If your artic s/author-reg /	(\$70.00/100 reprints) n your article. The costs to cle contains color figures, prints. Discover A / Exp.	publish those will use Rapid Ordering merican Express Date	U.S. address. Prices are subject t change without notice. Quantities over 500 copies: contact our Pharma Solutions Department at 410.528.4077 Outside the U.S. cal 4420.7981.0700
You may have included col be invoiced separately. www.lww.com/periodical. Payment MC VISA Account #	or figures in If your artic s/author-rep /	(\$70.00/100 reprints) n your article. The costs to cle contains color figures, prints. Discover A / Exp.	publish those will use Rapid Ordering merican Express Date	U.S. address. Prices are subject t change without notice. Quantities over 500 copies: contact our Pharma Solutions Department at 410.528.4077 Outside the U.S. cal 4420.7981.0700 MAIL your order to: Lippincott Williams
You may have included col be invoiced separately. www.lww.com/periodical. Payment MC VISA Account # Name Address City	or figures in If your artic s/author-rep / / State	(\$70.00/100 reprints) n your article. The costs to cle contains color figures, prints. Discover A / Exp. Dept/ Zip Count	publish those will use Rapid Ordering merican Express Date //Rm	<pre>U.S. address. Prices are subject t change without notice. Quantities over 500 copies: contact our Pharma Solutions Department at 410.528.4077 Outside the U.S. cal 4420.7981.0700 MAIL your order to: Lippincott Williams Wilkins Author Reprints Dept 351 W. Camden St. Baltimore, MD 21201</pre>
You may have included col be invoiced separately. www.lww.com/periodical. Payment MC VISA Account # Name Address City Telephone Signature	or figures in If your artic s/author-rep / /	(\$70.00/100 reprints) n your article. The costs to cle contains color figures, prints. Discover A / Exp. Dept/ Zip Count	publish those will use Rapid Ordering merican Express Date //Rm	<pre>U.S. address. Prices are subject t change without notice. Quantities over 500 copies: contact our Pharma Solutions Department at 410.528.4077 Outside the U.S. cal 4420.7981.0700 MAIL your order to: Lippincott Williams Wilkins Author Reprints Dept 351 W. Camden St. Baltimore, MD 21201 FAX: 410.528.4434</pre>
You may have included col be invoiced separately. www.lww.com/periodical Payment MC VISA Account # Name Address City Telephone Signature Ship to Name	or figures in If your artic s/author-rep / / State	(\$70.00/100 reprints) n your article. The costs to cle contains color figures, prints. Discover A / Exp. Dept/ Zip Count	publish those will use Rapid Ordering merican Express Date /Rm cry	<pre>U.S. address. Prices are subject t change without notice. Quantities over 500 copies: contact our Pharma Solutions Department at 410.528.4077 Outside the U.S. cal 4420.7981.0700 MAIL your order to: Lippincott Williams Wilkins Author Reprints Dept 351 W. Camden St. Baltimore, MD 21201 FAX: 410.528.4434 For questions regarding reprints o publication fees, E-MAIL: reprints@lww.com</pre>
You may have included col be invoiced separately. www.lww.com/periodical. Payment MC VISA Account # Name Address City Telephone Signature Ship to Name Address	or figures in If your artic s/author-reg / / State	(\$70.00/100 reprints) n your article. The costs to cle contains color figures, prints. Discover A / Exp. Dept/ Zip Count Dept/	Publish those will use Rapid Ordering merican Express Date //Rm :ry	<pre>U.S. address. Prices are subject t change without notice. Quantities over 500 copies: contact our Pharma Solutions Department at 410.528.4077 Outside the U.S. cal 4420.7981.0700 MAIL your order to: Lippincott Williams Wilkins Author Reprints Dept 351 W. Camden St. Baltimore, MD 21201 FAX: 410.528.4434 For questions regarding reprints o publication fees, E-MAIL: reprints@lww.com OR PHONE: 1 800 341 2258</pre>
You may have included col be invoiced separately. www.lww.com/periodical. Payment MC VISA Account # Name Address City Telephone Signature Ship to Name Address City	or figures in If your artic s/author-rep / / State State	(\$/0.00/100 reprints) n your article. The costs to cle contains color figures, prints. Discover A / Exp. Dept/ Zip Count Dept/ Zip Count	Publish those will use Rapid Ordering merican Express Date //Rm Cry	<pre>U.S. address. Prices are subject t change without notice. Quantities over 500 copies: contact our Pharma Solutions Department at 410.528.4077 Outside the U.S. cal 4420.7981.0700 MAIL your order to: Lippincott Williams Wilkins Author Reprints Dept 351 W. Camden St. Baltimore, MD 21201 FAX: 410.528.4434 For questions regarding reprints o publication fees, E-MAIL: reprints@lww.com OR PHONE: 1.800.341.2258</pre>

Copyright © 2007 The North American Menopause Society. Unauthorized reproduction of this article is prohibited.